# uMotif

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/umotif

- Industry: Software
- Headquarters: London, UK
- Website: www.umotif.com
- Total disclosed funding: $31M
- Latest round: Series B (May 25, 2022)
- Investors on record: 4

## About

uMotif Limited is a UK-based company providing electronic Clinical Outcome Assessment (eCOA) and electronic Patient Reported Outcome (ePRO) solutions, aimed at enhancing patient engagement in clinical and real-world research.Founded in 2012 and headquartered in London, UK, uMotif Limited delivers advanced solutions for clinical trials. It has raised GBP 20.000 mn in Series B funding led by Athyrium Capital Management, with previous support from AlbionVC and DNV GL. The company has secured three deals, the most recent occurring on May 25, 2022. Co-founders include Ben James, Bruce Hellman, and Dejorn Fisher, while Steve Rosenberg serves as the CEO.uMotif specializes in providing a modern electronic Clinical Outcome Assessment (eCOA) and electronic Patient Reported Outcome (ePRO) platform, along with eConsent solutions tailored for clinical and real-world research. The core product offerings include the uMotif app, which enables patients to track their symptoms and treatments, enhancing data capture and compliance. uMotif's solutions are utilized by various clients, including pharmaceutical companies and clinical research organizations, across over 30 therapeutic areas in Europe and Asia, supporting multiple languages from Arabic to Japanese.uMotif generates revenue through subscription-based models and partnerships with research organizations and pharmaceutical companies. Clients subscribe to its eCOA/ePRO platform for access during clinical trials. Revenue is primarily derived from licensing the uMotif app and related services, including ongoing support and analytics for monitoring patient engagement and data quality during trials.In May 2022, uMotif Limited raised GBP 20.000 mn in Series B funding, which will be used to further develop its software offerings for clinical research. The company aims to expand into new geographical markets and enhance its product line to improve clinical trial outcomes.

## Funding rounds

- Series B, May 25, 2022, $25M — Athyrium Capital Management, DNV, AlbionVC
- Series A, Jul 20, 2020, $6.3M — Albion Capital, DNV

## Investors

- Albion Capital — Series A
- DNV — Series A, Series B
- Athyrium Capital Management (https://capitalatlas.ai/funds/athyrium-capital-management) — Series B
- AlbionVC — Series B